CHEMOCENTRYX INC's ticker is CCXI and the CUSIP is 16383L106. A total of 205 filers reported holding CHEMOCENTRYX INC in Q3 2020. The put-call ratio across all filers is 0.50 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $1,482,000 | -45.9% | 110,700 | +107.1% | 0.02% | -45.2% |
| Q1 2021 | $2,740,000 | -17.2% | 53,465 | 0.0% | 0.03% | -11.4% |
| Q4 2020 | $3,311,000 | +3.5% | 53,465 | -8.4% | 0.04% | -7.9% |
| Q3 2020 | $3,200,000 | -4.8% | 58,396 | 0.0% | 0.04% | -17.4% |
| Q2 2020 | $3,360,000 | +33.0% | 58,396 | -7.1% | 0.05% | +7.0% |
| Q1 2020 | $2,526,000 | +42.8% | 62,870 | +40.5% | 0.04% | +79.2% |
| Q4 2019 | $1,769,000 | -88.9% | 44,732 | -98.1% | 0.02% | -88.1% |
| Q3 2019 | $15,982,000 | -8.7% | 2,357,203 | +25.3% | 0.20% | -6.9% |
| Q2 2019 | $17,499,000 | -35.9% | 1,881,609 | -4.3% | 0.22% | -31.8% |
| Q1 2019 | $27,303,000 | +104.4% | 1,965,639 | +60.5% | 0.32% | +57.4% |
| Q4 2018 | $13,359,000 | -18.8% | 1,224,429 | -5.9% | 0.20% | +45.3% |
| Q3 2018 | $16,450,000 | +21.7% | 1,301,410 | +26.8% | 0.14% | +37.6% |
| Q2 2018 | $13,514,000 | +154.7% | 1,026,137 | +163.0% | 0.10% | +173.0% |
| Q1 2018 | $5,305,000 | – | 390,097 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 276,400 | $4,726,000 | 1.88% |
| TANG CAPITAL MANAGEMENT LLC | 500,000 | $8,550,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 94,300 | $7,131,000 | 1.72% |
| Integral Health Asset Management, LLC | 300,000 | $5,130,000 | 1.48% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 139,200 | $2,380,000 | 1.35% |
| MANGROVE PARTNERS IM, LLC | 686,300 | $11,736,000 | 1.05% |
| Ikarian Capital, LLC | 600,000 | $10,261,000 | 0.72% |
| Ikarian Capital, LLC | 600,000 | $10,260,000 | 0.72% |
| Sofinnova Investments, Inc. | 517,708 | $8,853,000 | 0.52% |
| Birchview Capital, LP | 25,000 | $428,000 | 0.29% |